(Q37687325)

22 August 2017

1 reference

title

Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review (English)

1 reference

cost-effectiveness analysis

22 August 2017

1 reference

1 reference

Jack Brown

3

0 references

author name string

William A Prescott

series ordinal

1

1 reference

22 August 2017

Fred Doloresco

series ordinal

2

1 reference

22 August 2017

Joseph A Paladino

series ordinal

4

1 reference

22 August 2017

1 January 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

279-293

1 reference

22 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/11531860-000000000-00000

22 August 2017

0 references

cites work

Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11531860-000000000-00000

Palivizumab for preterm infants. Is it worth it?

21 January 2018

1 reference

12 December 2020

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

1 reference

12 December 2020

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

1 reference

12 December 2020

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab

1 reference

12 December 2020

Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina

1 reference

12 December 2020

Cost-effectiveness of palivizumab in New Zealand.

1 reference

12 December 2020

Identification and management of severe respiratory syncytial virus

1 reference

12 December 2020

Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

1 reference

12 December 2020

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

1 reference

12 December 2020

Prevention of respiratory syncytial virus infection with palivizumab

1 reference

12 December 2020

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

12 December 2020

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease

1 reference

12 December 2020

The cost and safety of multidose use of palivizumab vials

1 reference

12 December 2020

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection

1 reference

12 December 2020

Systematic review of the biology and medical management of respiratory syncytial virus infection

1 reference

12 December 2020

Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants

1 reference

12 December 2020

A cost-benefit analysis of RSV prophylaxis in high-risk infants

1 reference

12 December 2020

Administration of palivizumab: a medical provider's perspective.

1 reference

12 December 2020

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis

1 reference

12 December 2020

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area

1 reference

12 December 2020

Direct medical costs of bronchiolitis hospitalizations in the United States.

1 reference

12 December 2020

Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn

1 reference

12 December 2020

Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis

1 reference

12 December 2020

Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria

1 reference

12 December 2020

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

12 December 2020

Risk factors for bronchiolitis-associated deaths among infants in the United States

1 reference

12 December 2020

Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost

1 reference

12 December 2020

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

1 reference

12 December 2020

Strategies for preventing respiratory syncytial virus

1 reference

12 December 2020

Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants

1 reference

12 December 2020

Economic analysis of palivizumab in infants with congenital heart disease.

1 reference

12 December 2020

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

1 reference

12 December 2020

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

12 December 2020

Diagnosis and management of bronchiolitis

1 reference

12 December 2020

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

12 December 2020

The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations

1 reference

12 December 2020

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

1 reference

12 December 2020

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

1 reference

12 December 2020

Respiratory syncytial virus immune globulin: decisions and costs

1 reference

12 December 2020

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

12 December 2020

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

12 December 2020

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

12 December 2020

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

12 December 2020

Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis

1 reference

12 December 2020

Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands

1 reference

12 December 2020

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis

1 reference

12 December 2020

Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs

1 reference

12 December 2020

10.2165/11531860-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

0 references

1 reference